Management of Hepatocellular Cancer in the time of SARS‐CoV‐2

od Sharma, Rohini, Pinato, David J.
Izdano u Liver Int (2020)

Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?

od Hussain, Nadiya, Naeem, Muntaha, Pinato, David J.
Izdano u Hum Vaccin Immunother (2020)

Back from the brink: EGFR inhibition in gastroesophageal cancer

od Openshaw, Mark R., Pinato, David J., Valeri, Nicola
Izdano u Clin Cancer Res (2021)

Recent advances in HIV-associated Kaposi sarcoma

od Dalla Pria, Alessia, Pinato, David J., Bracchi, Margherita, Bower, Mark
Izdano u F1000Res (2019)

Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy

od Motedayen Aval, Leila, Pease, James E., Sharma, Rohini, Pinato, David J.
Izdano u J Clin Med (2020)

Clinical, Ethical and Financial Implications of Incidental Imaging Findings: Experience from a Phase I Trial in Healthy Elderly Volunteers

od Pinato, David J., Stavraka, Chara, Tanner, Mark, Esson, Audrey, Jacobson, Eric W., Wilkins, Martin R., Libri, Vincenzo
Izdano 2012

Programmed death ligand 1 (PD-L1) expression influences the immune-tolerogenic microenvironment in antiretroviral therapy-refractory Kaposi's sarcoma: A pilot study

od Mletzko, Salvinia, Pinato, David J., Robey, Rebecca C., Dalla Pria, Alessia, Benson, Peter, Imami, Nesrina, Bower, Mark
Izdano u Oncoimmunology (2017)

Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: Relationship with the hypoxic response, immune evasion and malignant behavior

od Pinato, David J., Black, James R., Trousil, Sebastian, Dina, Roberto E., Trivedi, Pritesh, Mauri, Francesco A., Sharma, Rohini
Izdano u Oncoimmunology (2017)

Blood Epstein–Barr virus DNA does not predict outcome in advanced HIV-associated Hodgkin lymphoma

od Ul-Haq, Ikram, Dalla Pria, Alessia, Suardi, Elisa, Pinato, David J., Froeling, Fieke, Forni, John, Randell, Paul, Bower, Mark
Izdano u Med Oncol (2018)

Antibiotic therapy and outcome from immune-checkpoint inhibitors

od Pinato, David J., Gramenitskaya, Daria, Altmann, Daniel M., Boyton, Rosemary J., Mullish, Benjamin H., Marchesi, Julian R., Bower, Mark
Izdano u J Immunother Cancer (2019)

Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms

od Fessas, Petros, Possamai, Lucia A., Clark, James, Daniels, Ella, Gudd, Cathrin, Mullish, Benjamin H., Alexander, James L., Pinato, David J.
Izdano u Immunology (2019)

Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy

od Pinato, David J., Shiner, Robert J., White, Solomon D. T., Black, James R. M., Trivedi, Pritesh, Stebbing, Justin, Sharma, Rohini, Mauri, Francesco A.
Izdano u Oncoimmunology (2016)

Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma

od Pinato, David J., Brown, Matthew W., Trousil, Sebastian, Aboagye, Eric O., Beaumont, Jamie, Zhang, Hua, Coley, Helen M., Mauri, Francesco A., Sharma, Rohini
Izdano u Br J Cancer (2019)

Prognostic sub-classification of intermediate-stage hepatocellular carcinoma: a multicenter cohort study with propensity score analysis

od Ramaswami, Ramya, Pinato, David J., Kubota, Keiichi, Ishizuka, Mitsuru, Arizumi, Tadaaki, Kudo, Masatoshi, Jang, Jeong Won, Kim, Young Woon, Pirisi, Mario, Allara, Elias, Sharma, Rohini
Izdano u Med Oncol (2016)

Immune-based therapies for hepatocellular carcinoma

od Pinato, David J., Guerra, Nadia, Fessas, Petros, Murphy, Ravindhi, Mineo, Takashi, Mauri, Francesco A., Mukherjee, Sujit K., Thursz, Mark, Wong, Ching Ngar, Sharma, Rohini, Rimassa, Lorenza
Izdano u Oncogene (2020)

Preliminary qualification of a novel, hypoxic-based radiologic signature for trans-arterial chemoembolization in hepatocellular carcinoma

od Pinato, David J., Pai, Madhava, Reccia, Isabella, Patel, Markand, Giakoustidis, Alexandros, Karamanakos, Georgios, Rushd, Azelea, Jamshaid, Shiraz, Oldani, Alberto, Grossi, Glenda, Pirisi, Mario, Tait, Paul, Sharma, Rohini
Izdano u BMC Cancer (2018)

An Inflammation Based Score Can Optimize the Selection of Patients with Advanced Cancer Considered for Early Phase Clinical Trials

od Pinato, David J., Stavraka, Chara, Flynn, Michael J., Forster, Martin D., O'Cathail, Séan M., Seckl, Michael J., Kristeleit, Rebecca S., Olmos, David, Turnbull, Samantha J., Blagden, Sarah P.
Izdano 2014

Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: a multi-center comparative...

od Pinato, David J., Arizumi, Tadaaki, Jang, Jeong Won, Allara, Elias, Suppiah, Puvan I., Smirne, Carlo, Tait, Paul, Pai, Madhava, Grossi, Glenda, Kim, Young Woon, Pirisi, Mario, Kudo, Masatoshi, Sharma, Rohini
Izdano u Oncotarget (2016)

Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib

od Howell, Jessica A., Pinato, David J., Ramaswami, Ramya, Arizumi, Tadaaki, Ferrari, Carlotta, Gibbin, Antonello, Burlone, Michela E., Guaschino, Giulia, Toniutto, Pierluigi, Black, James, Sellers, Laura, Kudo, Masatoshi, Pirisi, Mario, Sharma, Rohini
Izdano u Oncotarget (2017)

A Pilot Randomized, Placebo Controlled, Double Blind Phase I Trial of the Novel SIRT1 Activator SRT2104 in Elderly Volunteers

od Libri, Vincenzo, Brown, Andrew P., Gambarota, Giulio, Haddad, Jonathan, Shields, Gregory S., Dawes, Helen, Pinato, David J., Hoffman, Ethan, Elliot, Peter J., Vlasuk, George P., Jacobson, Eric, Wilkins, Martin R., Matthews, Paul M.
Izdano 2012